DNTHDianthus Therapeutics, Inc.
$82.35+124% 1Y
$82.35
$32.9252 weeks$115.67
The financials
Dianthus Therapeutics, Inc. by the numbers
For the full year FY2025, revenue was $2.0M (−67% year on year) and net income −$162M. Its largest product in Q4 2024 (quarter ended Dec 31, 2024) was License at $1.0M, 53% of the disclosed total, just ahead of License at 47%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | n/a | $193K | n/a |
| Operating income | −$61M | −$35M | n/a |
| Net income | −$50M | −$32M | n/a |
| Diluted EPS | −$0.90 | −$0.88 | n/a |
| Product | Revenue | Share |
|---|---|---|
| License | $1.0M | 53% |
| License | $900K | 47% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q2 2026Total $761.0K (+64%)
License grew +294% year on year
Segment Latestquarter on quarteryear on year
- License$761.0K$761.0Kquarter on quarter +64%year on year +294%+64%+294%
On our screens:Most shorted stocks